Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
- Sponsor:
- Pennsylvania State University
- Sponsor Study ID:
- BCC016
- CTO #:
- 103371
- NCT Number:
- NCT04696029
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Children
- Disease Sites:
- Brain and Nervous System
- Study Objectives:
- To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Kraveka, Jacqueline, at kravekjm@musc.edu .
- Study Coordinator, Kinder, Hannah, at kinderh@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina